Thomas Kunit

Thomas Kunit

Auto-generated profile, based on publicly available information

Thomas Kunit

Universitätsklinik für Urologie und Andrologie, Landeskrankenhaus Salzburg, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Österreich

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
ASAndreas Schörghofer
Andreas Schörghofer
MDMartin Drerup
Martin Drerup
TKThomas Kunit
Thomas Kunit
Lukas LusuardiLukas Lusuardi
Lukas Lusuardi
JHJosef Holzinger
Josef Holzinger
FWFrank Wolf
Frank Wolf
Rectal spacers are used to limit dose to the anterior rectal wall in high dose external beam radiation therapy of the prostate and have been shown to reduce radiation induced toxicity. Here we report the complication rate and toxicity of the implantation procedure in a large cohort of patients who have either received a gel- or balloon-type spacer. In total, 403 patients received rectal spacing, 264 with balloon, 139 with gel. Allocation was non-randomized. Two hundred seventy-six patients were treated with normofractionated regimen, the remaining 125 patients in moderate hypofractionation. Spacer related acute and late rectal toxicity was prospectively assessed by endoscopy using a mucosa scoring system (Vienna Rectoscopy Score) as well as CTCAE V.4. For the balloon subgroup, position and rotation of balloon spacers were additionally correlated to incidence and grade of rectal reactions in a post-hoc analysis of post-implant planning MRIs. Overall rectal toxicity was very low with average VRS scores of 0.06 at the day after implantation, 0.10 at the end of RT, 0.31 at 6 months and 0.42 at 12 months follow up. Acute Grade 3 toxicity (rectum perforation and urethral damage) directly related to the implantation procedure occurred in 1.49% (n = 6) and was seen exclusively in patients who had received the spacer balloon. Analysis of post implant MR imaging did not identify abnormal or mal-rotated positions of this spacer to be a predictive factors for the occurrence of spacer related G3 toxicities. Spacer technology is an effective means to minimize dose to the anterior rectal wall. However, the benefits in terms of dose sparing need to be weighed against the low, but possible risks of complications such as rectum perforation.

24 May 2014 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
Lukas LusuardiLukas Lusuardi
Lukas Lusuardi
MMMichael Mitterberger
Michael Mitterberger
SHStephan Hruby
Stephan Hruby
TKThomas Kunit
Thomas Kunit
BKBirgit Kloss
Birgit Kloss
GJGünter Janetschek
Günter Janetschek

9 November 2018 in BMC Urology
Verified
Journal Article
Open access
PDF file
MDMartin Drerup
Martin Drerup
AMAhmed Magdy
Ahmed Magdy
MHMartina Hager
Martina Hager
DCDaniela Colleselli
Daniela Colleselli
TKThomas Kunit
Thomas Kunit
MMMichael Mitterberger
Michael Mitterberger
Warm ischemia (WI) and bleeding constitute the main challenges for surgeons during laparoscopic partial nephrectomy (LPN). Current literature on the use of lasers for cutting and coagulation remains scarce and with small cohorts. We present the largest case series to date of non-ischemic LPN using a diode laser for small exophytic renal tumors. We retrospectively evaluated 29 patients with clinically localized exophytic renal tumors who underwent non-ischemic laser–assisted LPN with a 1318-nm wavelength diode laser. We started applying the laser 5 mm beyond the visible tumor margin, 5 mm away from the tissue in a non-contact fashion for coagulation and in direct contact with the parenchymal tissue for cutting. The renal vessels were not clamped, resulting in a WIT (warm ischaemic time) of 0 min, except for one case that required warm ischemia for 12 min and parenchymal sutures. No transfusion was needed, with a mean Hemoglobin drop of 1,4 mg/dl and no postoperative complications. The eGFR did not significantly change by 6 months. Histologically, the majority of lesions (n = 22/29) were renal-cell carcinoma stage pT1a. The majority of malignant lesions (n = 13/22) had a negative margin. However, margin interpretation was difficult in 9 cases due to charring of the tumor base. A mean follow-up of 1.8 years revealed no tumor recurrence. The mean tumor diameter was 19.4 mm. The 1318-nm diode laser has the advantages of excellent cutting and sealing properties when applied to small vessels in the renal parenchyma, reducing the need for parenchymal sutures. However, excessive smoke, charring of the surgical margin, and inability to seal large blood vessels are encountered with this technique.

15 September 2020 in Der Urologe
Verified
Journal Article
Open access
PDF file
SDSusanne Deininger
Susanne Deininger
THT. Herrmann
T. Herrmann
SSS. Schönburg
S. Schönburg
PTPeter Törzsök
Peter Törzsök
TKT. Kunit
T. Kunit
Lukas LusuardiLukas Lusuardi
Lukas Lusuardi
Zusammenfassung: Hintergrund: Bei einer alternden Gesellschaft ist mit einer Zunahme der therapiebedürftigen benignen Prostataobstruktion (BPO) zu rechnen, auch der Anteil an Patienten mit kardiovaskulären Komorbiditäten unter Antikoagulation steigt an. Hier kann die operative Therapie der BPO problematisch sein. Die blutstillende Wirkung der Techniken ist von besonderer Bedeutung. Fragestellung: Die folgende Übersichtsarbeit diskutiert die Datenlage zum Blutungsrisiko etablierter operativer Techniken und die Stellungnahme der EAU-Leitlinie „EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract symptoms (LUTS) incl. Benign Prostatic Obstruction (BPO)“ zu diesem Thema. Material und Methoden: Es wurde eine Datenanalyse aus PubMed erstellt. Ergebnisse: Die EAU-Leitlinie gibt der transurethralen Vaporisation der Prostata mittels Greenlight‑, Thulium- oder Diodenlaser und der Enukleation mittels Holmium- oder Thuliumlaser bei diesem Patientengut den Vorzug. Die bipolare ist der monopolaren transurethralen Resektion der Prostata (TURP) bei der Blutstillung überlegen. Die bipolare Enukleation der Prostata (BipoLEP) kann bei guter Hämostase zukünftig eine Alternative darstellen. Neuere minimal-invasive Techniken wie Urolift® (NeoTract, Pleasanton, USA), I‑TIND© (MediTate, Or-Akiva, Israel) und Rezūm™ (Boston Scientific, Boston, USA) zeigen ein geringes Blutungsrisiko, dies gilt auch für die Prostataarterienembolisation. Nicht geeignet erscheint die Aquaablation/AquaBeam® bei häufigen Nachblutungen. Die chirurgische Adenomektomie kann mit hoher Blutungsgefahr verbunden sein. Schlussfolgerung: Transurethrale Laservaporisation und -enukleation der Prostata sind die Therapie der Wahl beim antikoagulierten Patienten, jedoch haben auch andere transurethrale Techniken, wie die BipoLEP, ein akzeptables Blutungsrisiko und können je nach lokalen Ressourcen eine Alternative darstellen. Neuere minimal-invasive Ansätze können zukünftig mehr an Bedeutung gewinnen.

1 July 2014 in Research and Reports in Urology
Verified
Journal Article
Open access
LLLukas Lusuardi
Lukas Lusuardi
TKThomas Kunit
Thomas Kunit
An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia Thomas Kunit, Lukas LusuardiDepartment of Urology and Andrology, Paracelsus Medical University Salzburg, Salzburg, Austria In elderly men, benign prostatic hyperplasia is often associated with lower urinary tract symptoms, and its prevalence rises with age. Lower urinary tract symptoms can be very bothersome and lead to a decrease in health-related quality of life. Furthermore, benign prostatic hyperplasia is a progressive disease that can lead to serious complications like acute urinary retention. Medical treatment with α1-blockers or 5α-reductase inhibitors is recommended by the European Association of Urology. On the other hand, there are some new innovations such as NX1207. The aim of this review is to summarize the published data. NX1207 is a new drug that is administered by transrectal intraprostatic injection under ultrasound guidance. The substance leads to prostate volume reduction and symptomatic improvement. However, patient numbers are still low and currently treatment with NX1207 is still experimental.Keywords: BPH, NX 1207, hyperplasia, LUTS, prostate